問卷

TPIDB > Study Site

Study Site



National Taiwan University Cancer Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 106Taipei CityDa An

篩選

List

84Cases

2026-01-27 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F
  • Condition/Disease

    Oesophageal Squamous Cell Carcinoma

  • Test Drug

    ifinatamab deruxtecan (I-DXd)

Participate Sites
7Sites

Recruiting7Sites

2023-11-01 - 2035-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2023-11-15 - 2031-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Not yet recruiting9Sites

Recruiting1Sites

2023-12-01 - 2031-05-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2023-12-01 - 2027-12-31

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2027-06-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2024-01-01 - 2040-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-02-26 - 2037-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2024-04-15 - 2033-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting11Sites

2024-05-01 - 2033-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites